🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our #Lp(a) JAMA Insights article is out! ja.ma/3GnbYlc Dr Florian Kronenberg and I summarize the latest on Lp(a) testing and management The Kronenberg Lab International Atherosclerosis Society (IAS) European Atherosclerosis Society FH Europe Foundation

Insightful case series, congrats on getting it published. Anum Saeed Agnes Koczo

Finally, after two decades since it was approved, cardiologists are recognizing that ezetimibe is an incredible lipid-modulating drug that can drastically improve a statins performance and allows statins to be used at much lower doses msn.com/en-us/health/o… National Lipid Association

I wrote this JACC Journals because medicine should transcend borders & unite communities through shared purpose, evidence, and compassion. Words alone won’t change the world, but they can inspire actions and bring people together. jacc.org/doi/10.1016/j.… #GlobalHealth Yale School of Medicine

Today "a milestone in the evolution of personalized therapies for rare & ultra-rare inborn errors of metabolism" —the 1st human to undergo custom genome editing —outgrowth of decades of NIH funded research nejm.org/doi/full/10.10… nejm.org/doi/full/10.10… NEJM

The best way to gain recognition is not to build a personal brand. It’s to create a portfolio of work. Branding emphasizes how you want to be seen. Creating highlights what you can contribute. Image shouldn't be the goal. It should be a byproduct of pursuing worthwhile goals.

Very interesting talk on Familial Hypercholesterolemia with Anum Saeed at AL Chapter - ACC Annual Session.

Great to see old friends and make new ones at #nla2025 National Lipid Association Great meeting with highest attendance in NLA history. Lots of new information!

An underrated life lesson: Tolerance for uncertainty is the most valuable human trait. The greatest rewards in life go to those who can show up every single day even when the rewards are uncertain. The one who can tolerate the most uncertainty is the one who will eventually win.

Big news in #lipidology! Enlicitide, an oral PCSK9 inhibitor, significantly reduced LDL-C in both CORALreef HeFH & CORALreef Add-On Phase 3 trials. Led by NLA past-president Christie Ballantyne.👏 📄Read more: merck.com/news/merck-ann…

A new issue of Annals of Internal Medicine is online now. Read the latest at bit.ly/4iXoo26

Excellent work 👏👏

Two target trial emulation studies examined whether the GLP-1 receptor agonists #semaglutide and #dulaglutide are superior to #empagliflozin, an SGLT-2 inhibitor, in mortality and cardiovascular outcomes. Semaglutide was found to be more effective than empagliflozin in reducing

Print this free summary for patients explaining the findings of a new study that showed #semaglutide may give more benefit than empagliflozin to patients with type 2 diabetes who are at high risk for CVD. bit.ly/4ldGJIy

New JACC/ACC performance measures tighten LDL targets to <55 mg/dL for high-risk ASCVD—pushing earlier and more aggressive lipid management. Will this shift change clinician behavior in real-world prevention? Can we overcome existing inertia? jacc.org/doi/10.1016/j.…

Farhad Iman and colleagues present the Global Neurodegeneration Proteomics Consortium dataset – 250 million unique protein measurements from 35,000 samples. Samples were provided by 23 research communities. Authors identify proteins associated with AD, PD and ALS.

Wonderful to see! Deep respect to Nathan Wong & Erin D. Michos, M.D. for their outstanding leadership and stewardship of AJPC these past years. Khurram Nasir is an incredible mind and will bring innovation and genuine passion for moving the field forward. Congratulations! ASPC